ClinicalTrials.Veeva

Menu
M

MS & Neuromuscular Center of Excellence | Clearwater, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ocrelizumab
Tolebrutinib
Frexalimab
PERSEUS
PIPE-307
Siponimod
SAR441344
SAR442168
Tyrosine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple s...

Enrolling
Multiple Sclerosis, Primary Progressive
Drug: Ocrelizumab
Drug: Placebo

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Methylprednisolone
Drug: Antihistamine
Locations recently updated

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Enrolling
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple scler...

Active, not recruiting
Primary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose A

Trial sponsors

Novartis logo
Roche logo
Sanofi logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems